Last reviewed · How we verify
NCT06608407
Platelet Rich Plasma in the Prevention of Adhesion Reformation
NA trial testing PRP group in Intrauterine Adhesion in 46 participants. Enrolling by invitation.
11 April 2025
Quick facts
| Lead sponsor | Fu Xing Hospital, Capital Medical University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 10 October 2023 |
| Primary completion | 11 April 2025 |
| Estimated completion | 1 June 2025 |
| Sites | 2 locations across China |
Drugs / interventions tested
- PRP group
Conditions studied
- Intrauterine Adhesion — all drugs for Intrauterine Adhesion →
- Asherman Syndrome — all drugs for Asherman Syndrome →
Sponsor
Fu Xing Hospital, Capital Medical University
Who can join
Adults 20 to 40, female only, with Intrauterine Adhesion or Asherman Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Asherman syndrome, which occurs after trauma to the basalis layer of the endometrium. It seems that the role of postoperative platelet rich plasma（PRP）therapy in the prevention of recurrence of IUA is still controversial. To investigate if PRP therapy can prevent adhesion reformation after adhesiolysis. After the completion of hysteroscopic adhesiolysis, recruited patients will be randomized to one of the two treatment groups by computer-generated numbers: having PRP after hysteroscopic adhesiolysis; and the control group without PRP treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06608407
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PRP group
Trials testing the same drug.
- NCT04276818 — Use of Platelet-rich Plasma in Second-degree Superficial Burns · NA · completed
Other recruiting trials for Intrauterine Adhesion
Currently open trials in the same condition.
- NCT07421908 — Investigating the Association Between Diagnostic and Therapeutic Management Models and Prognosis of Intrauterine Adhesio · NA · recruiting
- NCT06645379 — Application of Platelet-rich Plasma (PRP) in Reproductive Medicine · NA · recruiting
- NCT05257213 — Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy · NA · recruiting
Other Fu Xing Hospital, Capital Medical University trials
Trials by the same sponsor.
- NCT06862089 — A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV · recruiting
- NCT05085067 — The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Rese · NA · recruiting
- NCT04835272 — Comparison of the Decannulation Protocol With Suctioning and Capping in Severe Acquired Brain Injury Patients · NA · unknown
- NCT04930913 — Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions · unknown
- NCT04936347 — Hysteroscopic "Hot Knife" and "Cold Knife" in the Treatment of the Intrauterine Adhesion · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06608407 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fu Xing Hospital, Capital Medical University
- Last refreshed: 11 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06608407.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing